⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMGN News
Amgen Inc
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
globenewswire.com
TEVA
AMGN
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
prnewswire.com
AMGN
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
prnewswire.com
AMGN
Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
prnewswire.com
AMGN
Zapata Quantum Adds Financial Veteran William Klitgaard to Board as Company Aims to Relist on National Exchange
globenewswire.com
ZPTA
XLNX
SYNH
AVST
CERT
BCRA
LHCG
AMZN
GOOG
MSFT
IBM
ORCL
MRK
DGX
ANTM
UNH
AMGN
GILD
BMY
PFE
ABBV
LRCX
KLAC
ADI
NXPI
QCOM
INTC
AMD
NVDA
MU
SMCI
CRWD
PANW
ZS
SNOW
DDOG
FTNT
TEAM
CRM
NOW
ADBE
INTU
PAYX
ADP
CTAS
WBA
CVS
CI
CNC
ELV
REGN
VRTX
BIIB
ALXN
AZN
NVS
ROG
SNY
XRAY
SYK
BSX
TMO
ILMN
EXAS
MDLZ
KHC
PEP
KO
MCD
SBUX
YUM
CMG
QSR
DNKN
LVS
WYNN
MGM
LULU
NKE
UA
ADDYY
PVH
RL
GPS
TJX
ROST
BBY
HD
LOW
SPG
PLD
AMT
EQIX
CCI
SBAC
PLTR
AI
UPST
SOFI
COIN
PYPL
SQ
AXP
V
MA
JPM
BAC
WFC
GS
MS
SCHW
ETFC
RJF
LPLA
BEN
IVZ
ABR
O
PSA
GOOGL
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
prnewswire.com
AMGN
COVID-19 Diagnostic Research Report 2025: 5 Year Forecast by Technology, Product, Channel and Country, with Executive and Consultant Guides - ResearchAndMarkets.com
businesswire.com
ABT
AMGN
BDX
BIO
CERN
DGX
DHR
ENZ
EXAS
GILD
HHC
HOLX
ILMN
ISRG
JNJ
LH
LMT
MRNA
MYL
NBIX
NOC
NTRA
NVTA
ONVO
ORCL
PDD
PFE
QGEN
QRVO
REGN
RHHBY
RMD
ROST
SGEN
SIGA
SNPS
SPLK
SRPT
STEM
SYK
TCOM
TGT
TMO
TSLA
TXG
VRTX
WBA
XRAY
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis Biotherapeutics - ResearchAndMarkets.com
businesswire.com
ABBV
INCY
AMGN
PFE
ACRT
Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight
prnewswire.com
AMGN
UCB
ENTX
RANI
ANGI
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
prnewswire.com
AMGN